Showing 1 - 9 results of 9 for search 'Drew Hannaman', query time: 0.04s Refine Results
  1. 1
    A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges

    A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protect... by Lesley C. Dupuy, Michelle J. Richards, Brian D. Livingston, Drew Hannaman, Connie S. Schmaljohn

    Published 2018-01-01
    Get full text
    Article
  2. 2
    An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice

    An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transge... by Callie E. Bounds, Frances E. Terry, Leonard Moise, Drew Hannaman, William D. Martin, Anne S. De Groot, John J. Suschak, Lesley C. Dupuy, Connie S. Schmaljohn

    Published 2017-12-01
    Get full text
    Article
  3. 3
    Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus.

    Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus. by Viktoria Stab, Sandra Nitsche, Thomas Niezold, Michael Storcksdieck Genannt Bonsmann, Andrea Wiechers, Bettina Tippler, Drew Hannaman, Christina Ehrhardt, Klaus Uberla, Thomas Grunwald, Matthias Tenbusch

    Published 2013-01-01
    Get full text
    Article
  4. 4
    The Safety and Immunogenicity of GTU®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART

    The Safety and Immunogenicity of GTU®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Supp... by G. Haidari, Suzanne Day, M. Wood, H. Ridgers, Alethea V. Cope, Sue Fleck, Celine Yan, Kalevi Reijonen, Drew Hannaman, Aggeliki Spentzou, Peter Hayes, A. Vogt, Behazine Combadiere, Adrian Cook, Sheena McCormack, Robin J. Shattock

    Published 2019-12-01
    Get full text
    Article
  5. 5
    Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

    Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. by Callie E Bounds, Steven A Kwilas, Ana I Kuehne, Jennifer M Brannan, Russell R Bakken, John M Dye, Jay W Hooper, Lesley C Dupuy, Barry Ellefsen, Drew Hannaman, Hua Wu, Jin-an Jiao, Eddie J Sullivan, Connie S Schmaljohn

    Published 2015-01-01
    Get full text
    Article
  6. 6
    A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.

    A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. by Aura R Garrison, Charles J Shoemaker, Joseph W Golden, Collin J Fitzpatrick, John J Suschak, Michelle J Richards, Catherine V Badger, Carolyn M Six, Jacqueline D Martin, Drew Hannaman, Marko Zivcec, Eric Bergeron, Jeffrey W Koehler, Connie S Schmaljohn

    Published 2017-09-01
    Get full text
    Article
  7. 7
    Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial

    Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical... by Poulam M. Patel, Christian H. Ottensmeier, Clive Mulatero, Paul Lorigan, Ruth Plummer, Hardev Pandha, Somaia Elsheikh, Efthymios Hadjimichael, Naty Villasanti, Sally E. Adams, Michelle Cunnell, Rachael L. Metheringham, Victoria A. Brentville, Lee Machado, Ian Daniels, Mohamed Gijon, Drew Hannaman, Lindy G. Durrant

    Published 2018-06-01
    Get full text
    Article
  8. 8
    A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

    A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations w... by Juliet Mpendo, Gaudensia Mutua, Julien Nyombayire, Rosine Ingabire, Annet Nanvubya, Omu Anzala, Etienne Karita, Peter Hayes, Jakub Kopycinski, Len Dally, Drew Hannaman, Michael A Egan, John H Eldridge, Kristen Syvertsen, Jennifer Lehrman, Beth Rasmussen, Jill Gilmour, Josephine H Cox, Patricia E Fast, Claudia Schmidt

    Published 2015-01-01
    Get full text
    Article
  9. 9
    Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

    Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine i... by Marnie L Elizaga, Shuying S Li, Nidhi K Kochar, Gregory J Wilson, Mary A Allen, Hong Van N Tieu, Ian Frank, Magdalena E Sobieszczyk, Kristen W Cohen, Brittany Sanchez, Theresa E Latham, David K Clarke, Michael A Egan, John H Eldridge, Drew Hannaman, Rong Xu, Ayuko Ota-Setlik, M Juliana McElrath, Christine Mhorag Hay, NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team

    Published 2018-01-01
    Get full text
    Article

Search Tools: